Seroconversion Following Nonoccupational Postexposure Prophylaxis against HIV

Roland, Michelle E.; Neilands, Torsten B.; Krone, Melissa R.; Katz, Mitchell H.; Franses, Karena; Grant, Robert M.; Busch, Michael P.; Hecht, Frederick M.; Shacklett, Barbara L.; Kahn, James O.; Bamberger, Joshua D.; Coates, Thomas J.; Chesney, Margaret A.; Martin, Jeffrey N.
November 2005
Clinical Infectious Diseases;11/15/2005, Vol. 41 Issue 10, p1507
Academic Journal
Background. The efficacy of antiretroviral postexposure prophylaxis (PEP) against infection with human immunodeficiency virus (HIV) following occupational exposures has prompted the use of PEP after nonoccupational exposures. There are, however, important differences between occupational and nonoccupational exposures, and the effectiveness of PEP following nonoccupational exposure is unknown. We sought to describe the occurrence and circumstances of HIV seroconversion following nonoccupational PEP. Methods. HIV uninfected individuals reporting potential sexual or injection drug use exposures to HIV in the preceding 72 h received a 28-day regimen of antiretroviral therapy and counseling in a nonrandomized trial. The level of HIV antibody was measured 12 weeks after PEP initiation. Results. Of 877 exposed subjects, 702 were evaluable 12 weeks after exposure. Seroconversion was detected in 7 subjects (1%; 95% confidence interval, 0.4%-2%). Three seroconverters reported having no exposures after PEP initiation and, thus, probably represent evidence of chemoprophylactic failure. In the other 4 subjects, additional exposures to HIV after PEP initiation or detection of HIV RNA in plasma specimens obtained at baseline precluded determination of the source of seroconversion. No exposure source was available to assess genetic concordance with the seroconverter's virus. Conclusions. As for occupational exposure, PEP is not completely effective in preventing HIV infection following nonoccupational exposure. Therefore, primary prevention remains essential. In contrast to the occupational setting, the potential source of exposure is rarely available for testing in the nonoccupational setting, and exposures are often not isolated. Thus, it is often impossible to determine whether seroconversion resulted from failure of PEP or from other exposures, posing difficulties for future comparative studies seeking to evaluate the effectiveness of PEP.


Related Articles

  • Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial. Altice, Frederick L.; Maru, Duncan Smith-Rohrberg; Bruce, R. Douglas; Springer, Sandra A.; Friedland, Gerald H. // Clinical Infectious Diseases;9/15/2007, Vol. 45 Issue 6, p770 

    Background. Directly administered antiretroviral therapy (DAART) is one approach to improve treatment adherence among human immunodeficiency virus (HIV)-infected drug users. Methods. In this randomized, controlled trial (ClinicalTrials.gov identifier, NCT00367172), the biological outcomes of a...

  • Global: clinical trial shows dramatic reduction in transmission of HIV as a result of treatment. Cozac, David // HIV/AIDS Policy & Law Review;Oct2011, Vol. 15 Issue 3, p31 

    The article reports on a clinical trial conducted by the U.S. HIV Prevention Trials Network which revealed that human immunopdeficiency virus (HIV)-positive persons' adherence to an effective antiretroviral therapy reduce the risk of virus transmission by 96 percent. The trial confirmed that HIV...

  • HIV Antiretroviral Postexposure Prophylaxis: A Cautionary Note. Cohen, Myron S.; Kashuba, Angela D. M.; Gay, Cynthia // Clinical Infectious Diseases;11/15/2005, Vol. 41 Issue 10, p1514 

    Presents the authors' opinions on the role of antiretroviral therapy in preventing the sexual transmission of human immunodeficiency virus (HIV) infection. Discussion on clinical trials to evaluate the efficacy of antiretroviral therapy; Views on the benefits of pre-exposure prophylaxis;...

  • Relationship between CD4+ Count and Non-AIDS Diseases in HIV Patients. Winslow, Dean L. // Infectious Disease Alert;Jun2008, Vol. 27 Issue 9, p101 

    EXACTLY 1397 ANTIRETROVIRAL (ARV) NAÏVE PATIENTS initiating ARVs, as part of a CPCRA-sponsored clinical trial (FIRST trial), were followed for a median of five years. Patients were randomized to one of three arms (NRTIs + PI, NRTIs + nnRTI, NRTIs + PI + nnRTI). CD4+ lymphocyte count, HIV RNA,...

  • Clinical and virological response to antiretroviral drugs among HIV patients on first-line treatment in Dar-es-Salaam, Tanzania. Mosha, Fausta; Ledwaba, Johanna; Ndugulile, Faustine; Ng'ang'a, Zipora; Nsubuga, Peter; Morris, Lynn; Kasubi, Mabula; Swai, Andrew; Vercauteren, Jurgen; Vandamme, Anne-Mieke // Journal of Infection in Developing Countries;Jul2014, Vol. 8 Issue 7, p845 

    Introduction: In Tanzania, the follow-up on antiretroviral therapy (ART) response is based on clinical outcomes. We investigated virological response and ARV resistance mutations in relation to clinical response in ARV-treated patients. Methodology: A cross-sectional study of a cohort of 150...

  • IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy—results from the ANRS CO4 cohort. Fontas, Eric; Kousignian, Isabelle; Pradier, Christian; Poizot-Martin, Isabelle; Durier, Christine; Weiss, Laurence; Levy, Yves; Costagliola, Dominique // Journal of Antimicrobial Chemotherapy (JAC);Oct2010, Vol. 65 Issue 10, p2215 

    Objectives: We investigated why, despite its beneficial effect on the CD4 cell count, IL-2 therapy had no clinical benefit as shown in the ESPRIT and SILCAAT trials. We focused on subgroups of patients defined according to CD4 cell counts at baseline and over time to assess the threshold above...

  • HIV Treatment as Prevention: Natural Experiments Highlight Limits of Antiretroviral Treatment as HIV Prevention. Wilson, David P. // PLoS Medicine;Jul2012, Vol. 9 Issue 7, p1 

    There is growing enthusiasm for increasing coverage of antiretroviral treatment among HIV-infected people for the purposes of preventing ongoing transmission. Treatment as prevention will face a number of barriers when implemented in real world populations, which will likely lead to the...

  • Physician Estimate of Antiretroviral Adherence in India: Poor Correlation with Patient Self-Report and Viral Load. Walshe, L.; Saple, D. G.; Mehta, S. H.; Shah, B.; Bollinger, R. C.; Gupta, A. // AIDS Patient Care & STDs;Mar2010, Vol. 24 Issue 3, p189 

    Adherence to antiretroviral therapy (ART) is critical in maintaining viral suppression and minimizing resistance in HIV-infected patients. We compared physician estimates of their patients' ART adherence with participant's self-reported adherence to determine patient-provider agreement and...

  • Altitudes to directly observed antiretroviral treatment in a workplace HIV care programme in South Africa. Page-Shipp, Liesi S.; Charalambous, Salome; Roux, Surita; Dias, Belinda; Sefuti, Clement; Churchyard, Gavin J.; Grant, Alison D. // Sexually Transmitted Infections;Aug2007, Vol. 83 Issue 5, p383 

    Objective: To investigate attitudes to directly observed antiretroviral therapy (DOT ART) among HIV infected adults attending a workplace HIV care programme in South Africa. Methods: Clients attending workplace HIV clinics in two regions were interviewed using a semi-structured questionnaire....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics